MAPT and amyloidosis: In the context of the current findings, it is thus possible that a TREM2-related neuroimmune response in ApoE4-carriers attenuates either an amyloid-induced deposition of tau pathology itself or the downstream consequences of tau that ultimately lead to neurodegeneration and cognitive decline [48].